Project Grant R21AI202446
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $218K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bozeman, MT 59717, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Montana State University $571,859 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify viral proteins driving orthobunyavirus neuropathogenesis. The research will leverage differences in neuropathogenic phenotypes among California Serogroup orthobunyaviruses—La Crosse virus (LACV), Jamestown Canyon virus (JCV), and Inkoo virus (INKV)—to determine which viral proteins mediate...
- The National Institute of Allergy and Infectious Diseases awarded Montana State University $560,708 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into the pathogenesis of neurobrucellosis. The award supports a five-year research project through July 31, 2031, examining how Brucella bacteria cross the blood-brain barrier, colonize the brain, and cause neurobrucellosis—the most severe complication of brucella infection in humans....
- The National Institute of Allergy and Infectious Diseases awarded the University of Montana $147,000 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop inter-strain recombinants of human cytomegalovirus as an in vitro model of in vivo genetic diversity. The project investigates genetic correlates of phenotypic variation in HCMV by generating and characterizing a recombinant library created through coinfection of cells with two genetically...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $664,076 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R01AI196089) to investigate the molecular mechanisms by which Staphylococcus aureus alpha-toxin impairs antigen-specific T cell response and adaptive immunity. The research examines how S. aureus alpha-toxin (HLA) functions as a virulence factor and potential vaccine target. The work...
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $423,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bacteriophage interactions with nontuberculous mycobacteria in mammalian cell intracellular environments. The research addresses the therapeutic use of bacteriophages—naturally occurring viruses that infect and kill bacteria—as an alternative treatment for drug-resistant nontuberculous...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $155,500 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate heterogeneity in Staphylococcus aureus virulence factor activity within neutrophils and its impact on bacterial survival and host-pathogen interactions. The research examines how an isogenic population of S. aureus generates bacteria with divergent outcomes upon interaction with...
- The National Institute of Allergy and Infectious Diseases awarded $130,199 to the University of California, San Diego on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate macrophage membrane-coated nanoparticles (MF-NPs) as adjuvant therapy for severe bacterial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). The research comprises two aims: testing in vitro whether MF-NPs modulate neutrophil responses to MRSA and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $186,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on infection-induced cell cycle diversion and macrophage inflammatory biogenesis. The award funds investigation into how bacterial infection of macrophages, specifically by methicillin-resistant Staphylococcus aureus (MRSA), triggers structural and biochemical...
- Federal Grant Award Summary Montana State University received a $1,153,952 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2029. This award supports fundamental research investigating the mechanisms and structures of hibernating ribosomes in Pseudomonas aeruginosa, an opportunistic pathogen responsible for persistent biofilm infections. The...
- The National Institute of Allergy and Infectious Diseases awarded Louisiana State University $599,480 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the regulation of neutrophil endoplasmic reticulum stress response by IRE1A in bacterial lung infection. The research addresses innate immune mechanisms that defend against methicillin-resistant Staphylococcus aureus (MRSA) lung infection, a drug-resistant pathogen causing mortality rates up...